Subcortical atrophy in frontotemporal dementia and Alzheimer’s disease

Significance for differential diagnosis and correlation with clinical manifestations

Renata Teles Vieira1, Leonardo Caixeta2

Abstract – Cerebral subcortical atrophy occurs in both Alzheimer’s disease (AD) and frontotemporal dementia (FTD) but its significance for clinical manifestations and differential diagnosis between these common types of dementia has not been extensively investigated. Objectives: To compare the severity of cerebral subcortical atrophy in FTD and AD and to analyze the correlations between cerebral subcortical atrophy and demographics and clinical characteristics. Methods: Twenty three patients with FTD and 21 with AD formed the sample, which comprised 22 men and 22 women, aged 33 to 89, with mean age (±SD) of 68.52±12.08 years, with schooling ranging from 1 to 20 years, with a mean (±SD) of 7.35±5.54 years, and disease duration with a mean (±SD) of 3.66±3.44 years. The degree of cerebral subcortical atrophy was measured indirectly with a linear measurement of subcortical atrophy, the Bifrontal Index (BFI), using magnetic resonance imaging. We evaluated cognition, activities of daily living and dementia severity with the Mini-Mental State Examination, Functional Activities Questionnaire and the Clinical Dementia Rating, respectively. Results: There was no significant difference (p>0.05) in BFI between FTD and AD. The severity of cognitive deficits (for both FTD and AD groups) and level of daily living activities (only for AD group) were correlated with BFI. Conclusions: A linear measurement of cerebral subcortical atrophy did not differentiate AD from FTD in this sample. Cognitive function (in both FTD and AD groups) and capacity for independent living (only in AD group) were inversely correlated with cerebral subcortical atrophy. Key words: frontotemporal dementia, Alzheimer’s disease, structural neuroimaging, subcortical atrophy.

Atrofia subcortical na demência frontotemporal e na doença de Alzheimer: importância para o diagnóstico diferencial e correlações com as manifestações clínicas

Resumo – Atrofia subcortical cerebral ocorre na doença de Alzheimer e na doença frontotemporal (DFT) mas sua importância para as manifestações clínicas e para o diagnóstico diferencial não foram amplamente investigadas. Objetivos: Comparar a gravidade da atrofia subcortical cerebral na DA e na DFT e analisar as correlações entre a atrofia subcortical cerebral e características demográficas e clínicas. Métodos: Vinte e três pacientes com diagnóstico de DFT e 21 com DA formaram a amostra que foi constituída por 22 homens e 22 mulheres, com idades entre 33 e 89 anos, idade média (±DP) de 68,52 (±12,08) anos, escolaridade variando de 1 a 20 anos, média de 7,35 (±5,54) e duração da doença com média de 3,66 (±3,44). O grau de atrofia subcortical foi avaliado indiretamente com uma medida linear de atrofia subcortical, o índice bifrontal (IBF) com o emprego de imagem por ressonância magnética. A cognição, atividades de vida diária e gravidade da demência foram avaliadas com o Mini-Exame do Estado Mental, Questionário de Atividades Funcionais e Escore Clínico de Demência, respectivamente. Resultados: O IBF não foi diferente entre os grupos com AD e DFT (p>0,05). A gravidade do transtorno cognitivo (tanto para DA como DFT) e as atividades de vida diária (apenas para DA) correlacionaram-se com o IBF. Conclusões: Uma medida linear de atrofia subcortical não foi diferente entre pacientes com DA e DFT nesta amostra. A cognição (na DA e na DFT) e a capacidade de vida independente (apenas na DA) correlacionaram-se inversamente com a atrofia subcortical cerebral. Palavras-chave: demência frontotemporal, doença de Alzheimer, neuroimagem estrutural, atrofia subcortical.
Diagnosis in life, of Alzheimer’s disease (AD) and Frontotemporal dementia (FTD) is made on clinical grounds, but currently used criteria are burdened with considerable subjective judgments, and yield an overall accuracy of 81% to 88% in AD cases. Given the high prevalence of both diseases and the increasing treatment options, simple and sensitive quantitative indicators of both forms of dementia in its early stages would represent valuable clinical tools. Measures of hippocampal atrophy have proven the most sensitive way of differentiating mild to moderate Alzheimer’s disease from non-demented elderly. Of these measures, the width of the temporal horn yields the highest sensitivity, predicting the disease in 73% of cases with 95% specificity.

Differentiation between FTD and AD on neuroimaging, however, remains a great challenge, especially in the clinical setting. Cerebral atrophy occurs in almost all types of dementia and is characterized by a loss of global cerebral volume that can be indirectly observed by ventricular and cerebral sulcal enlargement. Sensitive imaging providing linear and volumetric measures of atrophy rates have been proposed to track this decline. Generally these measures are larger in patients with dementia than in healthy elderly.

In this study, we aimed to better understand the relationship between the severity of cerebral subcortical atrophy and the type of dementia (FTD and AD), as well as to explore the relationship of age, duration and aggravation of dementia, educational level, daily living activities and cognition, with cerebral subcortical atrophy. Finally we test the usefulness of a linear measure of atrophy in differentiating AD from FTD.

Methods
Participants
A total of 44 participants diagnosed with dementia were recruited from the Clinicas Hospital at the Federal University of Goiás Medical School (FM-UFG), Brazil. There were no gender or ethnic restrictions. The study involved 22 men and 22 women, aged 33 to 89 years, with mean age (±SD) of 68.52±12.08 years, with schooling ranging from 1 to 20 years, with mean (±SD) of 7.35±5.54 years and disease duration with a mean (±SD) of 3.66±3.44 years.

The clinical diagnoses were reached by an experienced psychiatrist/neurologist (LC) based on patient history, neuroimaging and neuropsychological tests. Diagnosis of dementia was based on the criteria of the Diagnostic and Statistical Manual Mental Disorders, Fourth Edition (DSM-IV). Etiology of dementia included patients with Alzheimer’s disease (n=21) and Frontotemporal Dementia (n=23). Diagnosis of FTD was based on Neary et al. criteria while the diagnosis of probable AD was based on the National Institute of Neurological Disorders and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria. Prior to carrying out this research, approval by the local research ethics committee was obtained (protocol number: 006/05). All subjects who agreed to participate signed a written informed consent.

Instruments and procedures
Bifrontal index—BFI
Magnetic resonance was performed on a 1.5–T MRI unit with a quadrature head coil. T1-weighted sequences were analyzed for this study. From the axial slice of structural neuroimaging (Magnetic Resonance Imaging), the BFI was measured on a plane parallel to the temporal lobe plane at the level of the maximum width between the tips of the frontal horns of the lateral ventricles, and defined as the ratio of this value to the diameter of the inner skull table at the same level. The resulting ratio was then multiplied by 100 and expressed as a percentage (Figure 1).

Clinical Dementia Rating (CDR) – Dementia severity was determined by total on the Clinical Dementia Rating Scale. The CDR assesses cognitive function in six domains: memory, orientation judgment and problem solving, community affairs and personal care. Based on six scores, a

![Figure 1. Axial MR image showing the width between the frontal horns of the lateral ventricles (smaller arrows) and the cranial width (larger arrows) – Bifrontal Index.](image-url)
global CDR score is assigned in which CDR 0 indicates no dementia, CDR 0.5 indicates very mild dementia, CDR 1 indicates mild dementia, CDR 2 indicates moderate dementia, and CDR 3 indicates severe dementia.  

Mini-Mental State Examination (MMSE) – All patients completed the MMSE at baseline, which was administered to determine cognitive function.  

Pfeffer Functional Activities Questionnaire (FAQ) – Caregivers of dementia patients completed this questionnaire. It is a good instrument for assessing functional status, and includes ten questions on Activities of Daily Living (ADL).  

All 44 individuals were assessed using the BFI, CDR, MMSE and FAQ. Thus, duration of dementia and education level (in years) were also examined and served as inputs for the survival analysis. The neurological examination was performed during the same period as the clinical imaging. The patients were divided into two groups: one with FTD (n=23) and the other with AD (n=21). The BFI was compared in both groups for all analyzed variables.  

Statistical analysis  
We conducted all statistical analysis using the SPSS 12.0 software for Windows. The Mann-Whitney test (U) was performed to compare mean rates of variation between the two patient groups. The analyzed variables were: age, duration of dementia, MMSE scores, Functional Scale of Pfeffer’s scores, level of education in years, Clinical Dementia Rating Scale and BFI rate. We established the confidence interval as 95% for the statistical tests.  
The Spearman Coefficient (rs) was used to obtain the correlation p and to verify the correlations between mean rates of brain atrophy (measured by BFI) and all other variables. The Spearman’s Coefficient was the non-parametric alternative when the data was not Gaussian and linear.  

Results  
Table 1 shows the means (including standard deviation and confidence interval) of all the clinical features along with BFI for AD and FTD groups. Both patient groups were closely matched for age, duration of dementia, MMSE scores, Pfeffer Functional Activities Questionnaire (FAQ) scores and educational level. There was no significant difference in BFI between groups.  
In the FTD group, only the MMSE score showed a strong correlation with BFI (Table 2). The AD group also showed a significant correlation between MMSE score and BFI, but weaker than that observed in the FTD group. There was a significant correlation (p<0.05) between BFI *Denotes p value of <0.001; †Denotes modalities not significant (p>0.05); MMSE, Mini-Mental State Examination; BFI, Bifrontal Index; EPSs, Extrapyramidal Signs; FAQ, Pfeffer-Functional Activities Questionnaire; M, Mean; SD, Standard Deviation; CI, Confidence interval; Z, standard normal deviation.

| Table 2. Correlation of Bifrontal Index Rate with demographic factors, disease severity and the duration of symptoms in the two groups. |
|-----------------|-----------------|
| **BFI**         |                  |
| **Spearman's correlation (rs)** | **p value** |
| **Patients with Alzheimer's disease** | **Patients with frontotemporal dementia** |
| **Age, y** | **-0.246** | **0.016** |
| **Dementia duration, y** | **0.092** | **0.004** |
| **MMSE score** | **0.024** | **0.068** |
| **FAQ** | **0.028** | **0.075** |
| **Education, y** | **0.026** | **0.072** |

*Denotes p value of <0.005; †Denotes p value of <0.001; ‡ Differences of modalities not significant (p>0.05); MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating; BFI, Bifrontal Index; EPSs, Extrapyramidal Signs; FAQ, Pfeffer-Functional Activities Questionnaire.
and Pfeffer Functional Activities Questionnaire (FAQ) scores in the AD group only.

Age, duration of dementia and educational level were not correlated with BFI in either patient group (p<0.05). Other correlations were also not significant.

Discussion

Indirect measures of subcortical atrophy, such as the BFI, Bicaudate Index and Ventricule-Brain ratio have been reported by many researchers to evaluate structural brain damage in patients with dementia. Both linear and volumetric measurements are probably more reliable than those made postmortem when ventricles are usually smaller than the same ventricles before death.13-16,29,30

AD and FTD can be difficult to differentiate clinically because of overlapping symptoms. Distinguishing the two dementias based on volumetric measurements of brain atrophy with MRI has been only partially successful.9 Our study did not demonstrate BFI differences between AD and FTD groups.

Age was not correlated with rates of BFI in either group across all analyses performed. This finding is consistent with the results reported by Brinkman et al.35 in the study of quantitative indexes of computed tomography in 28 patients with Alzheimer’s dementia and 30 elderly persons. Nevertheless, other authors36 have shown that age-related increases in BFI most probably reflect losses in adjacent brain structures including the caudate nuclei in normal aging.

Concerning the analysis of cognitive performance, measured by the MMSE, there was a negative correlation with BFI in both patient groups, mainly in the FTD group (p<0.001). This finding is in line with previous reports in the literature that have shown distinct types of cerebral changes predicting impaired performance on specific cognitive tests.35-37 Soderlund et al.37 also observed that subcortical atrophy estimated by means of ventricular enlargement were associated with cognitive deficits. Nevertheless, the measures used in the cited study were the BFI, the Caudate Ventricular Index and Occipital Ventricular Index. The average of the three indexes was used to calculate a global score. Furthermore, the 1254 participants had an MMSE score above 24 and were non-demented individuals.

A small number of studies have focused attention on the relationship between activities of daily living and linear brain measures in dementia patients, but only in Vascular Dementia and normal aging.35,38 Activities of daily living performance decreased with increased subcortical atrophy only for the AD group. Perhaps, one explanation for this fact is that FTD patients present a reduced capacity to perform daily tasks from the early stages of disease (a difference from AD),39 when BFI values still remain low.

We found no correlation between duration of symp- toms and the linear measurement of subcortical atrophy. This may be expected because the extent of dementia is only an estimate. To our knowledge, no previous study has reported the association involving duration of dementia and subcortical atrophy measured by BFI.

We have also demonstrated that subcortical atrophy is not correlated with educational level. This could possibly be explained by the fact that participants had a large discrepancy in terms of years of education. Clinical pathologi- cal studies are necessary to clarify the association between subcortical atrophy and progression of dementia.

Studies including only one brain variable can be misleading because their putative association may be due to a correlated brain change while cerebral atrophy is an indirect measure of pathological processes occurring on a cellular level. In addition, the BFI is a non-specific finding which can result from brain injury or degeneration and which occurs normally in ageing, although many disease processes result in distinctive patterns of atrophy due to differential involvement of specific areas of the brain.

In conclusion, a linear measurement of subcortical atrophy such as BFI probably is not useful for providing a differential diagnosis between AD and FTD. Furthermore, cognitive function (in both FTD and AD groups) and capacity for independent living (only in AD group) decreased with increased subcortical atrophy. Our findings also revealed that age, duration of dementia and educational level do not significantly correlate with degree of cerebral atrophy.

References
1. Rascovsky K, Hodges JR, Kipps CM, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord 2007;21:S14-S18.
2. Kazee AM, Eskin TA, Lapham LW, Gabriel KR, McDaniel KD, Hamill RW. Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria. Alz Dis Assoc Disord 1993;3:152–164.
3. Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer’s disease: a clinicopathologic study of 57 cases. Neurology 1988;38:359–364.
4. Hogan DB, Bailey P, Black S, et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ 2008;179:787-793.
5. Bocci C, Rockel C, Roy P, Gao F, Black SE. Topographical patterns of lobar atrophy in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord 2006;21:364-372.
6. Perry RJ; Hodges R. Differentiating frontal and temporal variant frontotemporal dementia from Alzheimer’s disease. Neurology 2000;54:2277-2284.
7. Lindau M, Almkvist O, Johansson SE, Wahlund LO. Cognitive
and behavioral differentiation of frontal lobe degeneration of the non-Alzheimer type and Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:205-213.
8. Lipton AM, Benavides R, Hynan LS, et al. Localization on neuroimaging does not differentiate frontotemporal lobar degeneration from Alzheimer’s disease. Dement Geriatr Cogn Disord 2004;17:324-327.
9. Du AT, Schuff N, Kramer JH, et al. Different regional patterns of cortical thinning in Alzheimer’s disease and frontotemporal dementia. Brain 2007;130:1159-1166.
10. Varma AR, Adams W, Lloyd JJ, et al. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer’s disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 2002;105:261-269.
11. Julin P, Wahlund LO, Basun H, Persson A, Måre K, Rudberg U. Clinical diagnosis of frontal lobe dementia and Alzheimer’s disease: relation to cerebral perfusion, brain atrophy and electroencephalography. Dementia 1995;6:142-147.
12. Akyama H, Meyer JS, Mortel KF, Terayama Y, Thorony JI, Konno S. Normal human aging: factors contributing to cerebral atrophy. J Neurol Sci 1997;152:39-49.
13. Synyk V, Reuben JR. The ventricle-brain ratio using planimetric measurement of EMI scans. Br J Radiol 1976;49:233-237.
14. Heinz ER, Ward A, Drayer BP, Dubois PJ. Distinction between obstructive and atrophic dilatation of ventricles in children. J Comput Assist Tomogr 1980;4:320-325.
15. Aylward EH, Swartz J, Machlin S, Pearlson G. Bicaudate Ratio as a Measure of Caudate Volume on MR Images. Am J Neuroradiol 1991;12:1217-1222.
16. Frisoni GB, Beltramello A, Weiss C, Geroldi C, Bianchetti A, Trabucci M. Linear Measures of Atrophy in Mild Alzheimer Disease. Am J Neuroradiol 1996;17:913-923.
17. Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer’s disease. Lancet 2004;363:362-394.
18. Chaves MLF, Maia ALG, Lehmen R, Oliveira LM. Dementia and normal aging: clinical relevance of braintemrs and cognitive performance in a Brazilian sample. Braz J Med Biol Res 1999;32:1133-1143.
19. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
20. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association; 1994.
21. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
22. McKhann G; Drachman D; Folstein M; Katzman R; Price D; Stadlan EM. Clinical Diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 1984;34:939-944.
23. Baar AN, Heinze WJ, Dobben GD, Valvassori GE, Sugar O. Bicaudate index computerized tomography of Huntington disease and cerebral atrophy. Neurology 1978;28:1196-1200.
24. Hahn FY, Rim K. Frontal Ventricular Dimensions on Normal Computed Tomography. AJR Am J Roentgenol 1976;126:593-596.
25. Zhang Y, Wahlund, LH. Lean Frontal Horns Ratio- A New Linear Measurement to predict early cerebral atrophy on CT. Neurobiol Aging 2004;25:371-372.
26. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State". A practical method for grading the cognitive state of patients for clinician. J Psychiatr Research 1975;12:189-198.
27. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontology 1982;37:323-329.
28. Bigler ED, Hubler DW, Cullum CM, Turkheimer E. Intellectual and Memory in Dementia. Computed Axial Topography Volume Correlations. J Nerv Ment Dis 1985;173:347-354.
29. Woods BT, Douglass A, Gescuk B. Is the VBR still a useful measure of changes in the cerebral ventricle? Psychiatry Research: Neuroimaging 1991;40:1-10.
30. Brinkman SD, Sarwar M, Levin HS, Morris HH. Quantitative indexes of computed tomography in dementia and normal aging. Radiology 1981;138:89-92.
31. Doraiswamy PM, Patterson L, Na C, et al. Bicaudate index on magnetic resonance imaging: effects of normal aging. J Geriatr Psychiatry Neurol 1994;7:13-17.
32. Söderlund H, Nilsson L-G, Berger K, et al. Cerebral changes on MRI and cognitive functions: The CASCADE study. Neurobiol Aging 2006;27:16-23.
33. Laakson MP, Soininm H, Partanen K, et al. Volumes of hippocampus, amygdala and frontal lobes in the MRI-bases diagnosis of early Alzheimer’s disease: Correlation with memory functions. J Neural Transm 1995;9:73-86.
34. Laakson MP, Soininm H, Partanen K, et al. MRI of the Hippocampus in Alzheimer’s disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging 1998;19:23-31.
35. Broderick JP, Gaskill M, Dhawan A, Khoury JC. Temporal changes in brain volume and cognition in a randomized treatment trial of vascular dementia. J Neuroimaging 2001;11:6-12.
36. Mioshi E, Kipps CM, Dawson K, Mitchell J, Graham A, Hodges JR. Activities of daily living in frontotemporal dementia and Alzheimer disease. Neurology 2007;68:2077-2084.
37. Laakson MP, Soininm H, Partanen K, et al. MRI of the Hippocampus in Alzheimer’s disease: Sensitivity, Specificity, and Analysis of the Incorrectly Classified Subjects. Neurobiol Aging 1998;19:23-31.
38. Broderick JP, Gaskill M, Dhawan A, Khoury JC. Temporal changes in brain volume and cognition in a randomized treatment trial of vascular dementia. J Neuroimaging 2001;11:6-12.
39. Mioshi E, Kipps CM, Dawson K, Mitchell J, Graham A, Hodges JR. Activities of daily living in frontotemporal dementia and Alzheimer disease. Neurology 2007;68:2077-2084.